Login | Register
Profile | Log out
logo

  • Home
  • News
  • Opinion
  • Other
    • Market Updates
    • Explainers
    • Satire
  • About
  • Contact Us
    • Contact
    • Get Covered
    • Posting Guidelines
  • Subscribe
Submit An Article

Blog

  • Home
  •  
  • Blog



  • Most Read
  • Latest Comments
  • Blog
    • News

    RBA and ASIC up the ante on blockchain project, ASX writes off millions
    Public
  • Blog
    • Satire

    Australia to close borders to Omicron Persei 8
    Public
  • Blog
    • Opinion

    The New Criterion: will the listed sanitiser stocks clean up – or clean out – investors?
    Public
  • Blog
    • Opinion

    Is this the most hated company on the ASX?
    Public
  • Blog
    Opening a new frontier in treating Parkinson’s disease
    • Review
    • November 11, 2022
  • Tremors from the FTX collapse continue to be felt as DigitalX sells off 15% Bitcoin holdings
    • Review
    • January 10, 2023
  • AUDC stablecoin gathers momentum as Novatti confirms integration with XRP Ledger
    • Review
    • June 9, 2022
  • PharmAust completes dosing first cohort for MND treatment, patients respond positively
    • Review
    • January 6, 2023
  • Is this the most hated company on the ASX?
    • Review
    • August 16, 2019

Latest Articles

  • AML3D announces stronger FY26, with positive EBITDA reported in the second half
    AML3D announces stronger FY26, with positive EBITDA reported in the second half
    • News

  • Refurbished tech gives Harris Technology a second life
    Refurbished tech gives Harris Technology a second life
    • News

  • Imagion Biosystems Advances MagSense® Phase 2 Trial
    Imagion Biosystems Advances MagSense® Phase 2 Trial
    • News

  • Acrux-developed Menopause Hormone Therapy to enter Australian market
    Acrux-developed Menopause Hormone Therapy to enter Australian market
    • News

  • Evion Expands Critical Minerals Push with Nevada Fluorspar Option
    Evion Expands Critical Minerals Push with Nevada Fluorspar Option
    • News

  • Osprey secures GE Healthcare for global distribution of kidney imaging tech
    • News

    Osprey secures GE Healthcare for global distribution of kidney imaging tech

    Medtech company Osprey Medical (ASX: OSP) has significantly increased its global distribution network having secured distribution of their kidney imaging portfolio by partnering with global giant GE Healthcare.  Under the 4-year agreement, GE will commercialise Osprey’s DyeVert portfolio which reduces the amount of contrast that reaches the kidney for imaging, and will assist medical professionals

    Read More
    Public
  • Lowest inflation read in Australia’s 72-year CPI history
    • News

    Lowest inflation read in Australia’s 72-year CPI history

    The Consumer Price Index (CPI) fell 1.9% in the June 2020 quarter according to the Australian Bureau of Statistics (ABS), with an annual deflation rate of 0.3%. Since 1949, this was only the third time annual inflation has been negative. The previous times were in 1962 and 1997-98. The June quarter fall was mainly the

    Read More
    Public
  • Boom or bust: retailing’s two-speed economy
    • Opinion

    Boom or bust: retailing’s two-speed economy

    Shoppers engaging in retail therapy despite the spectre of even more serious job losses and mounting evidence the virus is far from vanquished. According to the Australian Bureau of Statistics, retail sales rose 2.4 per cent for the month of June, to $29.7 billion. This was an 8 per cent rise on the previous June

    Read More
    Public
  • SUDA gains regulatory approval for sale of insomnia treatment spray
    • News

    SUDA gains regulatory approval for sale of insomnia treatment spray

    Australians suffering from insomnia could soon have relief from the disorder with SUDA Pharmaceuticals (ASX: SUD) gaining approval from the Therapeutics Goods Administration (TGA) for the sale of their ZolpiMist spray as a treatment for short-term insomnia.  The regulatory approval enables ZolpiMist to be sold in Australia and will assist their strategic partners in other

    Read More
    Public
  • Silver ratio returns to key level
    • Opinion

    Silver ratio returns to key level

    It can’t be this easy, can it? There is a large community of traders who focus purely on trading precious metals, with the weapons of choice being gold and silver. These precious metals are named as such because they are rare, beautiful, and have been desired by humans for the entirety of recorded history. In

    Read More
    Public
  • Cellmid secures US distribution to 40,000 salons for anti-aging hair care
    • News

    Cellmid secures US distribution to 40,000 salons for anti-aging hair care

    Australian health and biotech company Cellmid (ASX: CDY) is set to capitalise on rising health product retail sales in the United States having secured an exclusive distribution partnership with Tru Beauty Concepts and their network of 40,000 hair salons.  The 5-year distribution deal will provide Cellmid with access to Tru Beauty salons across 11 US

    Read More
    Public
  • «
  • ‹
  • 589
  • 590
  • 591
  • 592
  • 593
  • ›
  • »

Login or register for free to access unlimited reading

Register Now!
  • News

  • Opinion

  • Satire

  • About

  • Contact Us

  • Subscribe

The content published on this website is solely for general information purposes and is not to be construed as financial advice. Should you seek financial advice you should consult with an appropriately qualified person. Opinions expressed on this site are subject to change without notice and The Sentiment who produced this content is under no obligation to keep the information current. The Sentiment, affiliated companies & associates may have a conflict of interest with companies discussed on the website due to commercial arrangements, for example they may be shareholders in the company, be engaged by them to assist in investor communications or receive commission/brokerage for funds raised.

Copyright © 2020 The Sentiment. All rights reserved.
Subscribe

Enter your email address below to subscribe to The Sentiment’s weekly newsletter, highlighting the top news, research, opinion and satire articles shaping ASX investor sentiment.

The Sentiment respects your privacy and will not spam you. View our privacy policy here.